1. Home
  2. MNY vs PDSB Comparison

MNY vs PDSB Comparison

Compare MNY & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MoneyHero Limited

MNY

MoneyHero Limited

HOLD

Current Price

$0.69

Market Cap

38.4M

Sector

N/A

ML Signal

HOLD

Logo PDS Biotechnology Corporation

PDSB

PDS Biotechnology Corporation

HOLD

Current Price

$0.81

Market Cap

42.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNY
PDSB
Founded
2014
2005
Country
Singapore
United States
Employees
N/A
10
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.4M
42.4M
IPO Year
2023
2015

Fundamental Metrics

Financial Performance
Metric
MNY
PDSB
Price
$0.69
$0.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$4.00
★ $9.00
AVG Volume (30 Days)
30.0K
★ 44.9M
Earning Date
04-30-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 28.16
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$19.58
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.60
$0.20
52 Week High
$1.60
$1.55

Technical Indicators

Market Signals
Indicator
MNY
PDSB
Relative Strength Index (RSI) 23.42 68.88
Support Level N/A $0.58
Resistance Level $0.91 $1.07
Average True Range (ATR) 0.05 0.14
MACD -0.01 0.05
Stochastic Oscillator 23.95 73.77

Price Performance

Historical Comparison
MNY
PDSB

About MNY MoneyHero Limited

MoneyHero Ltd is a tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia. It operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. The company has four operating and reportable segments: Hong Kong, Singapore, the Philippines, and Taiwan. The Hong Kong segment generates the majority of the revenue.

About PDSB PDS Biotechnology Corporation

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.

Share on Social Networks: